+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dysmenorrhea - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5180474
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 185 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2020

FEATURED COMPANIES

  • Fuji Pharma
  • Myovant Sciences/Takeda
  • Nippon Shinyaku
  • ObsEva
  • Pure Green
  • MORE
This ‘Dysmenorrhea-Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU-5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The dysmenorrhea market report provides current treatment practices, emerging drugs, Dysmenorrhea market share of the individual therapies, current and forecasted Dysmenorrhea market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Dysmenorrhea treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2030

Dysmenorrhea: Disease Understanding and Treatment Algorithm

Dysmenorrhea Overview

Painful menstrual periods in medical term are described as Dysmenorrhea, which is often called as “menstrual cramps” in simpler terms. Dysmenorrhea can be classified into two types: Primary Dysmenorrhea and Secondary Dysmenorrhea. Primary dysmenorrhea is common menstrual cramps related to the normal process of menstruation. These cramps are recurrent and are not due to other diseases. Pain can range from mild to severe, can typically last 12-72 hours, and can be accompanied by nausea and vomiting, fatigue, and even diarrhea. Whereas, in secondary dysmenorrhea the pain is caused by any disorder in the woman's reproductive organs. Pain usually begins earlier in the menstrual cycle and lasts longer than common menstrual cramps. Contrary to the primary dysmenorrhea, in this type pain is not typically accompanied by nausea, vomiting, fatigue, or diarrhea. The most common cause of secondary dysmenorrhea is endometriosis.

Dysmenorrhea is common in women from every age and region; however, certain risk factors which add to the increased risk are smoking, consuming alcohol during their menstrual cycle, being overweight or obese, sexual abuse, Low body mass index, etc.

Dysmenorrhea Diagnosis

The diagnosis for dysmenorrhea involves the doctor analyzing the menstrual history of the patient along with their family history too, followed by conducting tests such as MRI, Ultrasound, and Laparoscopy, etc., if needed.

Dysmenorrhea Treatment

The treatment pattern can be broadly divided into three parts: Pharmacological treatment, surgery and Non- Pharmacological treatment. Pharmacological treatment comprises the use of nonsteroidal anti-inflammatory drugs (NSAIDs), hormonal contraception and Gonadotropin-releasing hormone (GnRH) analogs. Whereas, currently used Non-pharmacological practice includes the use Transcutaneous electrical nerve stimulation (TENS) and Supportive Therapies.

Dysmenorrhea Epidemiology

The Dysmenorrhea epidemiology division provides the insights about historical and current Dysmenorrhea patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Dysmenorrhea epidemiology [segmented as Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea), Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea, Severity-specific Prevalent Cases of Primary dysmenorrhea, Severity-specific Prevalent Cases of Secondary dysmenorrhea, Treated cases of Primary and Secondary Dysmenorrhea] scenario of Dysmenorrhea in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise-Dysmenorrhea Epidemiology
  • In the year 2017, the total prevalent cases of Dysmenorrhea were 134,524,953 in the 7MM. The United States, in 2017, accounted for 58,670,651 cases (the highest number among the 7MM countries).
  • Among the EU-5 countries, the highest number of cases of Dysmenorrhea were in Germany, i.e., 13,122,996 cases in the year 2017, which is estimated to rise by the year 2030.
  • Spain accounted for the least number of prevalent cases, i.e., 445,364 cases in 2017.
  • Among the 7MM, Japan accounted for 18,442,399, and 2,410,771 Primary and Secondary Dysmenorrhea cases, respectively in 2017.
Dysmenorrhea Drug Chapters

Drug chapter segment of the Dysmenorrhea report encloses the detailed analysis of Dysmenorrhea marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Dysmenorrhea clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Dysmenorrhea Emerging Drugs

Relugolix: Myovant Sciences GmbH/ Takeda
Myovant Sciences is developing its potential drug Relugolix, which is a small molecule consumed orally and its mechanism of action includes acting as a GnRH receptor antagonist, for the treatment of uterine fibroids and endometriosis. Relugolix is the most anticipated phase III program for the treatment of endometriosis-associated pain. For this candidate, Takeda has commercial rights for Japan along with some parts of Asia. In other regions, Myovant Sciences holds commercialization rights. Myovant was formed by Takeda and Roivant Sciences in June 2016.

Yselty (Linzagolix; OBE2109): ObsEva
Yselty (previously known as Linzagolixx, OBE2109) by ObsEva is a novel, oral, once-daily, GnRH receptor antagonist with the tagline best-in-class profile. As per the company, the aspect which makes it different from the other marketed GnRH, is that it has the potential to provide effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.

FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
FSN-013 is a 5th generation combined oral contraceptive drug of Fuji Pharma composed of estetrol (a natural estrogen) and drospirenone. As of now, it has exhibited some of the eye-catching characteristics such as improved bleeding control as compared to other drugs. Along with this, it also has lower lipid impact, and lower interaction among other drugs.

Pure Femme Tablets: Pure Green
Pure Green Pharmaceuticals is an emerging the US-based biotech start-up, at the forefront of research into the therapeutic qualities of cannabis. Currently, a phase II (NCT04091789) clinical trial is in its recruiting stage which is anticipated to include 30 patients.

Dysmenorrhea Market Outlook

Key Findings

According to the publisher, Dysmenorrhea market in the 7MM is expected to change in the study period 2017-2030.The therapeutic market of Dysmenorrhea in seven major markets was found to be USD 7,430 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of Dysmenorrhea therapies was found to be USD 4,582 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of Dysmenorrhea therapies was found to be USD 2,071 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of Dysmenorrhea therapies in Japan was found to be USD 777 million in 2017.

Dysmenorrhea Pipeline Development Activities

The drugs which are in pipeline includes:
  • Yselty (Linzagolix; OBE2109): ObsEva: Phase III
  • Relugolix (TAK-385): Myovant Sciences/Takeda: Phase III
  • Pure Femme Tablets: Pure Green: Phase II
  • FSN-013 (Estetrol/ Drospirenone): Fuji Pharma: Phase II
Pipeline Development Activities

Key Points
  • In October 2019, Myovant Sciences completed the patient recruitment process for its ongoing phase III SPIRIT 1 clinical trial assessing the safety and effectiveness of Relugolix in combination with estradiol and progestin to treat pain in women with endometriosis.
  • In May 2018, Takeda Pharmaceuticals and ASKA Pharmaceutical entered into a licensing agreement to grant ASKA exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned Relugolix.
Dysmenorrhea Drugs Uptake

Among emerging therapies, Relugolix data from SPIRIT 1 and SPIRIT 2 looks promising and expected to garner the highest market share. On a cross-trial basis, efficacy of Relugolix is in line with a high Orilissa dose, but without the same association with hot flushes and bone density loss.

Access and Reimbursement Scenario in Dysmenorrhea Therapies
  • For easy access, Patient Assistance Program (PAP) help patients with limited resources. It is worth noting that, the Company's myAbbVie Assist provides free medicines to qualified patients. Eligible patients are the ones that have been prescribed Orilissa, have limited or no health insurance coverage, live in the United States, and are being treated by a licensed US health care provider on an outpatient basis.
  • Direct healthcare costs for managing endometriosis associated pain and indirect costs to patients, employers, and society due to loss of employment and productivity, are substantial. Dysmenorrhea and endometriosis associated pain, are a significant cost burden for payers in the US healthcare system because hysterectomy - the common curative treatment - is associated with high hospitalization costs. There is a lack of reimbursement policies for most of the therapies; however, by considering the unavailability of effective treatments, the reimbursement of therapies for Dysmenorrhea could be less complicated in the near future.
KOL - Views

To keep up with current market trends, the researchers take KOLs and SME's opinion working in Dysmenorrhea domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dysmenorrhea market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The researchers perform Competitive and Market Intelligence analysis of the Dysmenorrhea Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Dysmenorrhea, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Dysmenorrhea epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Dysmenorrhea are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Dysmenorrhea market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dysmenorrhea market.
Report Highlights
  • In the coming years, Dysmenorrhea market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Dysmenorrhea. Launch of emerging therapies, will significantly impact the Dysmenorrhea market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dysmenorrhea.
  • the in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Dysmenorrhea Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Dysmenorrhea Pipeline Analysis
  • Dysmenorrhea Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Dysmenorrhea Report Key Strengths
  • 11 Years Forecast
  • 7MMCoverage
- Dysmenorrhea Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Dysmenorrhea Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the Dysmenorrhea Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Dysmenorrhea total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Dysmenorrhea market size during the study period (2017-2030)?
  • At what CAGR, the Dysmenorrhea market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the Dysmenorrhea market outlook across the 7MM during the study period (2017-2030)?
  • What would be the Dysmenorrhea market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Dysmenorrhea patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Dysmenorrhea market?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the Dysmenorrhea?
  • What is the historical Dysmenorrhea patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Dysmenorrhea in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dysmenorrhea?
  • Out of all the 7MM countries, which country would have the highest prevalent population of Dysmenorrhea during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Dysmenorrhea?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the treatment of Dysmenorrhea along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Dysmenorrhea in the US, Europe and Japan?
  • What are the Dysmenorrhea marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Dysmenorrhea?
  • How many therapies are developed by each company for the treatment of Dysmenorrhea?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Dysmenorrhea?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dysmenorrhea therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dysmenorrhea and their status?
  • What are the key designations that have been granted for the emerging therapies for Dysmenorrhea?
  • What are the global historical and forecasted market of Dysmenorrhea?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Dysmenorrhea market.
  • To understand the future market competition in the Dysmenorrhea market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Dysmenorrhea in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Dysmenorrhea market.
  • To understand the future market competition in the Dysmenorrhea market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Fuji Pharma
  • Myovant Sciences/Takeda
  • Nippon Shinyaku
  • ObsEva
  • Pure Green
  • MORE
1. Key Insights

2. Executive Summary of Dysmenorrhea

3. SWOT Analysis

4. Epidemiology and Market Methodology

5. Dysmenorrhea: Market Share (%) Distribution Overview at a Glance: By Country

6. Dysmenorrhea: Disease Background and Overview
6.1. Types of Dysmenorrhea
6.2. Risk Factors
6.3. Signs and Symptoms
6.4. Pathophysiology
6.5. Diagnosis
6.6. Diagnostic Algorithm
6.7. Diagnostic Guidelines
6.7.1. National Institute for Health and Care Excellence (NICE) Guidelines

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM
7.3.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM
7.3.3. Severity-specific Prevalent Cases of Dysmenorrhea in the 7MM
7.3.4. Treated cases of Primary and Secondary Dysmenorrhea in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States
7.4.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States
7.4.3. Severity-specific Prevalent Cases of Dysmenorrhea in the United States
7.4.4. Treated cases of Primary and Secondary Dysmenorrhea in the United States
7.5. EU-5 Epidemiology
7.6. Germany
7.6.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany
7.6.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany
7.6.3. Severity-specific Prevalent Cases of Dysmenorrhea in Germany
7.6.4. Treated cases of Primary and Secondary Dysmenorrhea in Germany
7.7. France
7.7.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France…
7.7.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France
7.7.3. Severity-specific Prevalent Cases of Dysmenorrhea in France
7.7.4. Treated cases of Primary and Secondary Dysmenorrhea in France
7.8. Italy
7.8.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy
7.8.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy
7.8.3. Severity-specific Prevalent Cases of Dysmenorrhea in Italy
7.8.4. Treated cases of Primary and Secondary Dysmenorrhea in Italy
7.9. Spain
7.9.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain
7.9.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain
7.9.3. Severity-specific Prevalent Cases of Dysmenorrhea in Spain
7.9.4. Treated cases of Primary and Secondary Dysmenorrhea in Spain
7.10. The United Kingdom
7.10.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom
7.10.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom
7.10.3. Severity-specific Prevalent Cases of Dysmenorrhea in the United Kingdom
7.10.4. Treated cases of Primary and Secondary Dysmenorrhea in the United Kingdom
7.11. Japan Epidemiology
7.11.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan
7.11.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan
7.11.3. Severity-specific Prevalent Cases of Dysmenorrhea in Japan
7.11.4. Treated cases of Primary and Secondary Dysmenorrhea in Japan

8. Current Treatment Practices
8.1. Pharmacological Treatments
8.1.1. NSAIDs
8.1.2. Hormonal contraception
8.1.3. Gonadotropin-releasing hormone (GnRH) analogs
8.2. Surgery
8.2.1. Removal of the uterus (hysterectomy) and ovaries (oophorectomy)
8.2.2. Laparoscopic uterine nerve ablation and laparoscopic presacral neurectomy
8.3. Non-Pharmacological Treatments
8.3.1. Transcutaneous electrical nerve stimulation (TENS)
8.3.2. Supportive Therapies
8.4. Treatment Algorithms
8.5. Guideline of Dysmenorrhea
8.5.1. American College of Obstetricians and Gynecologists (ACOG) recommendations for Dysmenorrhea and Endometriosis in the Adolescent
8.5.2. NICE Recommendations: Endometriosis (2017)
8.5.3. Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition
8.5.4. Guideline of the European Society of Human Reproduction and Embryology (ESHRE) for Endometriosis-associated pain: 2013

9. Unmet Needs

10. Patient Journey

11. Key Endpoints in Dysmenorrhea Clinical Trials

12. Marketed Therapies
12.1. Marketed Key Cross
12.2. Orilissa (Elagolix): AbbVie/ Neurosciences Biosciences
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activities
12.2.4. Pivotal Clinical Trial
12.2.5. Ongoing Clinical Trial Activity
12.3. Jemina Tablets (levonorgestrel – ethinylestradiol compound formulation): Nobelpharma/ASKA Pharmaceutical
12.3.1. Product Description
12.3.2. Regulatory Milestones
12.4. Visanne (Dinagest): Mochida/Bayer Schering Pharma AG
12.4.1. Product Description
12.4.2. Regulatory Milestones
12.4.3. Other Developmental Activities
12.4.4. Pivotal Clinical Trials

13. Emerging Therapies
13.1. Yselty (Linzagolix; OBE2109): ObsEva
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.2. Relugolix (TAK-385): Myovant Sciences/Takeda
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.3. Pure Femme Tablets: Pure Green
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.4. FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Safety and Efficacy
13.5. NS-580: Nippon Shinyaku
13.5.1. Product Description
13.5.2. Clinical Development

14. Conjoint Analysis of Dysmenorrhea Therapies

15. Dysmenorrhea: Seven Major Market Analysis
15.1. Key Findings
15.2. Market Outlook

16. 7MM Market Size
16.1. Total Market Size of Dysmenorrhea in the 7MM
16.2. Total Market size of Dysmenorrhea by Therapies in the 7MM

17. United States Market Size
17.1. Total Market size of Dysmenorrhea in the United States

18. EU-5 Market Size
18.1. Germany Market Size
18.1.1. Total Market size of Dysmenorrhea in Germany
18.2. France Market Size
18.2.1. Total Market size of Dysmenorrhea in France
18.3. Italy Market Size
18.3.1. Total Market size of Dysmenorrhea in Italy
18.4. Spain Market Size
18.4.1. Total Market size of Dysmenorrhea in Spain
18.5. United Kingdom Market Size
18.5.1. Total Market size of Dysmenorrhea in the United Kingdom

19. Japan Market Size
19.1. Total Market size of Dysmenorrhea in Japan

20. Market Access and Reimbursement of Dysmenorrhea Therapies

21. Market Drivers

22. Market Barriers

23. Appendix
23.1. Bibliography
23.2. Report Methodology
23.3. Publisher Capabilities

24. Disclaimer

25. About the Publisher

List of Tables
Table 1 Summary of Dysmenorrhea Market, Epidemiology, and Key Events (2017-2030)
Table 2 Stages of Endometriosis
Table 3 Differential Diagnosis of Dysmenorrhea
Table 4 NICE Recommendations
Table 5 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM (2017-2030)
Table 6 Total Prevalent Cases of Primary and Secondary Dysmenorrhea in the 7MM (2017-2030)
Table 7 Total Diagnosed cases of Dysmenorrhea, and its types (Primary dysmenorrhea, and Secondary dysmenorrhea) in the 7MM (2017-2030)
Table 8 Severity-specific Prevalent Cases of Primary dysmenorrhea in the 7MM (2017-2030)
Table 9 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the 7MM (2017-2030)
Table 10 Total Treated cases of Primary and Secondary Dysmenorrhea in the 7MM (2017-2030)
Table 11 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
Table 12 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
Table 13 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United States (2017-2030)
Table 14 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United States (2017-2030)
Table 15 Total Treated cases of Primary and Secondary Dysmenorrhea in the United States (2017-2030)
Table 16 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
Table 17 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
Table 18 Severity-specific Prevalent Cases of Primary dysmenorrhea in Germany (2017-2030)
Table 19 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Germany (2017-2030)
Table 20 Total Treated cases of Primary and Secondary Dysmenorrhea in Germany (2017-2030)
Table 21 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
Table 22 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
Table 23 Severity-specific Prevalent Cases of Primary dysmenorrhea in France (2017-2030)
Table 24 Severity-specific Prevalent Cases of Secondary dysmenorrhea in France (2017-2030)
Table 25 Total Treated cases of Primary and Secondary Dysmenorrhea in France (2017-2030)
Table 26 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
Table 27 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
Table 28 Severity-specific Prevalent Cases of Primary dysmenorrhea in Italy (2017-2030)
Table 29 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Italy (2017-2030)
Table 30 Total Treated cases of Primary and Secondary Dysmenorrhea in Italy (2017-2030)
Table 31 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
Table 32 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
Table 33 Severity-specific Prevalent Cases of Primary dysmenorrhea in Spain (2017-2030)
Table 34 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Spain (2017-2030)
Table 35 Total Treated cases of Primary and Secondary Dysmenorrhea in Spain (2017-2030)
Table 36 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
Table 37 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
Table 38 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United Kingdom (2017-2030)
Table 39 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United Kingdom (2017-2030)
Table 40 Total Treated cases of Primary and Secondary Dysmenorrhea in the United Kingdom (2017-2030)
Table 41 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
Table 42 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
Table 43 Severity-specific Prevalent Cases of Primary dysmenorrhea in Japan (2017-2030)
Table 44 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Japan (2017-2030)
Table 45 Total Treated cases of Primary and Secondary Dysmenorrhea in Japan (2017-2030)
Table 46 Marketed Key Cross
Table 47 Orilissa; Clinical Trial Description, 2020
Table 48 Yselty (Linzagolix; OBE2109) Clinical Trial Description, 2020
Table 49 Relugolix (TAK-385); Clinical Trial Description, 2020
Table 50 Pure Femme Tablets, Clinical Trial Description, 2020
Table 51 FSN-013; Clinical Trial Description, 2020
Table 52 NS-580, Clinical Trial Description, 2020
Table 53 7MM Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 54 7MM Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 55 Total United States Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 56 United States Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 57 Germany Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 58 Germany Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 59 France Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 60 France Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 61 Italy Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 62 Italy Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 63 Spain Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 64 Spain Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 65 United Kingdom Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 66 United Kingdom Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
Table 67 Japan Market Size of Dysmenorrhea, in USD Million (2017-2030)
Table 68 Japan Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)

List of Figures
Figure 1 Dysmenorrhea SWOT Analysis
Figure 2 Dysmenorrhea
Figure 3 Types of Dysmenorrhea
Figure 4 Endometriosis
Figure 5 Uterine fibroids
Figure 6 Adenomyosis
Figure 7 Risk Factors
Figure 8 Symptoms
Figure 9 Pathophysiology of Adolescent dysmenorrhea
Figure 10 Laparoscopy
Figure 11 Hysteroscopy
Figure 12 Diagnostic Algorithm
Figure 13 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM (2017-2030)
Figure 14 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM (2017-2030)
Figure 15 Severity-specific Prevalent Cases of Primary dysmenorrhea in the 7MM (2017-2030)
Figure 16 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the 7MM (2017-2030)
Figure 17 Total Treated cases of Primary and Secondary Dysmenorrhea in the 7MM (2017-2030)
Figure 18 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
Figure 19 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
Figure 20 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United States (2017-2030)
Figure 21 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United States (2017-2030)
Figure 22 Treated cases of Primary and Secondary Dysmenorrhea in the United States (2017-2030)
Figure 23 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
Figure 24 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
Figure 25 Severity-specific Prevalent Cases of Primary dysmenorrhea in Germany (2017-2030)
Figure 26 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Germany (2017-2030)
Figure 27 Treated cases of Primary and Secondary Dysmenorrhea in Germany (2017-2030)
Figure 28 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
Figure 29 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
Figure 30 Severity-specific Prevalent Cases of Primary dysmenorrhea in France (2017-2030)
Figure 31 Severity-specific Prevalent Cases of Secondary dysmenorrhea in France (2017-2030)
Figure 32 Treated cases of Primary and Secondary Dysmenorrhea in France (2017-2030)
Figure 33 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
Figure 34 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
Figure 35 Severity-specific Prevalent Cases of Primary dysmenorrhea in Italy (2017-2030)
Figure 36 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Italy (2017-2030)
Figure 37 Treated cases of Primary and Secondary Dysmenorrhea in Italy (2017-2030)
Figure 38 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
Figure 39 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
Figure 40 Severity-specific Prevalent Cases of Primary dysmenorrhea in Spain (2017-2030)
Figure 41 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Spain (2017-2030)
Figure 42 Treated cases of Primary and Secondary Dysmenorrhea in Spain (2017-2030)
Figure 43 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
Figure 44 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
Figure 45 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United Kingdom (2017-2030)
Figure 46 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United Kingdom (2017-2030)
Figure 47 Treated cases of Primary and Secondary Dysmenorrhea in the United Kingdom (2017-2030)
Figure 48 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
Figure 49 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
Figure 50 Severity-specific Prevalent Cases of Primary dysmenorrhea in Japan (2017-2030)
Figure 51 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Japan (2017-2030)
Figure 52 Treated cases of Primary and Secondary Dysmenorrhea in Japan (2017-2030)
Figure 53 Stepwise approach to treat dysmenorrhea
Figure 54 Treatments Options for Dysmenorrhea
Figure 55 Contraceptive Vaginal Ring
Figure 56 Common IUD Types
Figure 57 Effects of GnRH antagonists
Figure 58 Recommended points for TENS therapy
Figure 59 Flowchart for the management of patients with dysmenorrhea.
Figure 60 Treatment algorithm for dysmenorrhea.
Figure 61 Treatment pathway for women presenting with dysmenorrhea in primary care
Figure 62 An endometriosis treatment algorithm
Figure 63 Unmet Needs of Dysmenorrhea
Figure 64 Patient Journey
Figure 65 Market Size of Dysmenorrhea in the 7MM, in USD Million (2017-2030)
Figure 66 Market Size of Dysmenorrhea in the 7MM by Therapy, in USD Million (2017-2030)
Figure 67 Total Market Size of Dysmenorrhea in the United States, in USD Million (2017-2030)
Figure 68 Market Size of Dysmenorrhea in the United States by Therapy, in USD Million (2017-2030)
Figure 69 Total Market Size of Dysmenorrhea in Germany, in USD Million (2017-2030)
Figure 70 Market Size of Dysmenorrhea in Germany by Therapies, in USD Million (2017-2030)
Figure 71 Total Market Size of Dysmenorrhea in France, in USD Million (2017-2030)
Figure 72 Market Size of Dysmenorrhea in France by therapies, in USD Million (2017-2030)
Figure 73 Total Market Size of Dysmenorrhea in Italy, in USD Million (2017-2030)
Figure 74 Market Size of Dysmenorrhea in Italy by Therapies, in USD Million (2017-2030)
Figure 75 Total Market Size of Dysmenorrhea in Spain, in USD Million (2017-2030)
Figure 76 Market Size of Dysmenorrhea in Spain by therapies, in USD Million (2017-2030)
Figure 77 Total Market Size of Dysmenorrhea in the United Kingdom by Therapies, in USD Million (2017-2030)
Figure 78 Market Size of Dysmenorrhea in the United Kingdom by Therapies, in USD Million (2017-2030)
Figure 79 Total Market Size of Dysmenorrhea in Japan, in USD Million (2017-2030)
Figure 80 Market Size of Dysmenorrhea in Japan by Therapy, in USD Million (2017-2030)
Figure 81 Market Drivers
Figure 82 Market Barriers
Note: Product cover images may vary from those shown
  • AbbVie/ Neurosciences Biosciences
  • Nobelpharma/ASKA Pharmaceutical
  • ObsEva
  • Myovant Sciences/Takeda
  • Pure Green
  • Fuji Pharma
  • Nippon Shinyaku
Note: Product cover images may vary from those shown
Adroll
adroll